Related Experiment Video
Updated: Jun 16, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
Fabry disease and G6PD in three family members with priapism: is the nitric oxide pathway to blame?
Rebecca Backenroth1, Ezekiel H Landau, Miri Goren
1Department of Nephrology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Insights
Priapism may be a clinical symptom of Fabry disease, a genetic disorder affecting multiple systems. The nitric oxide pathway may link Fabry disease and glucose-6-phosphate dehydrogenase deficiency to priapism.
Area of Science:
- Genetics and rare diseases
- Vascular biology
- Metabolic disorders
Background:
- Fabry disease is an X-linked disorder caused by alpha-galactosidase A deficiency, leading to glycosphingolipid accumulation.
- This accumulation primarily affects vascular endothelium, impacting cardiovascular, renal, and neurologic systems.
Observation:
- A familial cluster of priapism was observed in three males with Fabry disease and glucose-6-phosphate dehydrogenase (G6PD) deficiency.
- Literature review identified six additional cases of priapism in males with Fabry disease and two with G6PD deficiency.
Findings:
- Priapism is a rare but reported manifestation in males within the Fabry registry.
- A potential link between Fabry disease, G6PD deficiency, and priapism is suggested through derangements in the nitric oxide (NO) pathway.
Implications:
- Priapism should be considered a potential clinical symptom in patients with Fabry disease.
- Fabry disease warrants inclusion in the differential diagnosis for priapism.
- Further research is needed to elucidate the role of NO metabolism in Fabry disease manifestations, especially concerning G6PD deficiency.
Introduction:
Fabry disease is an X-linked multisystem disorder due to alpha galactosidase A deficiency leading to glycosphingolipid accumulation with a predilection for the vascular endothelium and affecting the cardiovascular, renal, and neurologic systems.
Aim:
To report a familial cluster of priapism in three males from a family with Fabry disease and glucose-6-phosphate dehydrogenase (G6PD) deficiency and discuss possible mechanisms.
Methods:
Patient charts, Fabry registry, and literature review.
Results:
Priapism has been reported in 6 males among the 1,558 males of the Fabry registry. Eight additional case reports of priapism in patients with Fabry disease and two reports of patients with G6PD were collected from the literature. Derangement in the nitric oxide (NO) pathway, which can occur in both Fabry disease and G6PD, is suggested as a hypothesis for the priapism in our patients.
Conclusions:
It is suggested that priapism should be included in the list of clinical symptoms of Fabry patients and that Fabry disease should be added to the differential diagnosis of priapism. Furthermore, the association of G6PD and Fabry disease with priapism emphasizes the need for further study to explore the role of NO metabolism in the etiology of Fabry disease manifestations.
More Related Videos
Related Concept Videos
Nitric Oxide Signaling Pathway
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Antihypertensive Drugs: Vasodilators
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Activation and Inactivation of G Proteins

